Distribution of Dopamine D2-Like Receptors in the Human Thalamus: Autoradiographic and PET Studies

Neuropsychopharmacology

Volumn 29, Issue 2, 2004, Pages 362-372

  Rieck, Richard W ^a   Ansari, M S ^a   Whetsell Jr , William O ^a   Deutch, Ariel Y ^a,b,c   Kessler, Robert M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

Dopamine; Epidepride; Midline thalamic nuclei; Paraventricular thalamic nucleus; Parkinson's disease; Prefrontal cortex

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; EPIDEPRIDE; BENZAMIDE DERIVATIVE; IODINE; N ((1 ALLYL 2 PYRROLIDINYL)METHYL) 5 (3 FLUOROPROPYL) 2,3 DIMETHOXYBENZAMIDE; N-((1-ALLYL-2-PYRROLIDINYL)METHYL)-5-(3-FLUOROPROPYL)-2,3-DIMETHOXYBENZAMIDE; PYRROLIDINE DERIVATIVE;

ADULT; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; COGNITION; FOREBRAIN; HUMAN; HUMAN TISSUE; HYPOTHALAMUS; ISOTOPE LABELING; MALE; NERVE CELL; POSITRON; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR DENSITY; REWARD; THALAMUS; THALAMUS INTRALAMINAR NUCLEUS; THALAMUS NUCLEUS; THALAMUS PARAFASCICULAR NUCLEUS; BINDING SITE; BRAIN MAPPING; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HISTOLOGY; METABOLISM; METHODOLOGY; MIDDLE AGED; SCINTISCANNING; TISSUE DISTRIBUTION;

ADULT; AUTORADIOGRAPHY; BENZAMIDES; BINDING SITES; BRAIN MAPPING; HUMANS; IODINE ISOTOPES; MALE; MIDDLE AGED; PYRROLIDINES; RECEPTORS, DOPAMINE D2; THALAMUS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0842286588     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300336     Document Type: Article

References (88)

1. Andreasen NC (1997). The role of the thalamus in schizophrenia. Can J Psychiatry 42: 27-33.
2. Berendse HW, Groenewegen HJ (1990). Organization of the thalamostriatal projections in the rat, with special emphasis on the ventral striatum. J Comp Neurol 299: 187-228.
3. Berendse HW, Groenewegen HJ (1991). Restricted cortical termination fields of the midline and intralaminar thalamic nuclei in the rat. Neuroscience 42: 73-102.
4. Bolton RF, Cornwall J, Phillipson OT (1993). Collateral axons of cholinergic pontine neurones projecting to midline, mediodorsal and parafascicular thalamic nuclei in the rat. J Chem Neuroanat 6: 101-114.
5. Bosler O, Beaudet A, Denoroy L (1987). Electron-microscopic characterization of adrenergic axon terminals in the diencephalon of the rat. Cell Tissue Res 248: 393-398.
6. Brown EE, Robertson GS, Fibiger HC (1992). Evidence for conditional neuronal activation following exposure to a cocaine-paired environment: role of forebrain limbic structures. J Neurosci 12: 4112-4121.
7. Bubser M, Deutch AY (1998). Thalamic paraventricular nucleus neurons collateralize to innervate the prefrontal cortex and nucleus accumbens. Brain Res 787: 304-310.
8. Buchsbaum MS, Someya T, Teng CY, Abel L, Chin S, Najafi A et al (1996). PET and MRI of the thalamus in never-medicated patients with schizophrenia. Am J Psychiatry 153: 191-199.
9. Byne W, Buchsbaum MS, Mattiace LA, Hazlett EA, Kemether E, Elhakem SL et al (2002). Postmortem assessment of thalamic nuclear volumes in subjects with schizophrenia. Am J Psychiatry 159: 59-65.
10. Calabresi P, Pisani A, Centonze D, Bernardi G (1997). Synaptic plasticity and physiological interactions between dopamine and glutamate in the striatum. Neurosci Biobehav Rev 21: 519-523.
11. Calderazzo L, Cavalheiro EA, Macchi G, Molinari M, Bentivoglio M (1996). Branched connections to the septum and to the entorhinal cortex from the hippocampus, amygdala, and diencephalon in the rat. Brain Res Bull 40: 245-251.
12. Choi WS, Machida CA, Ronnekleiv OK (1995). Distribution of dopamine D1, D2, and D2 receptor mRNAs in the monkey brain: ribonuclease protection assay analysis. Mol Brain Res 31: 86-94.
13. Christian BT, Narayanan TK, Shi B, Mukherjee J (2000). Quantitation of striatal and extrastriatal D-2 dopamine receptors using PET imaging of [(18)F]fallypride in nonhuman primates. Synapse 38: 71-79.
14. 3H]GABA. Neuroscience 22: 425-439.
15. Chudler EH, Dong WK (1995). The role of the basal ganglia in nociception and pain. Pain 60: 3-38.
16. Ciliax BJ, Drash GW, Staley JK, Haber S, Mobley CJ, Miller GW et al (1999). Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol 409: 38-56.
17. Cohen BM, Wan W, Froimowitz MP, Ennulat DJ, Cherkerzian S, Konieczna H (1998). Activation of midline thalamic nuclei by antipsychotic drugs. Psychopharmacology (Berl) 135: 37-43.
18. Cohen BM, Yurgelun-Todd D (2001). Alterations of thalamic activity in schizophrenia and in response to antipsychotic drugs: studies in the legacy of Seymour S. Kety. Neuropsychopharmacology 25: 305-312.
19. Delforge J, Bottlaender M, Loc'h C, Dolle F, Syrota A (2001). Parametric images of the extrastriatal D2 receptor density obtained using a high-affinity ligand (FLB 457) and a double-saturation method. J Cereb Blood Flow Metab 21: 1493-1503.
20. Deutch AY, Bubser M, Young CD (1998). Psychostimulant-induced Fos protein expression in the thalamic paraventricular nucleus. J Neurosci 18: 10680-10687.
21. Deutch AY, Goldstein M, Baldino Jr F, Roth RH (1988). The telencephalic projections of the A8 dopamine cell group. Ann NY Acad Sci 537: 27-50.
22. Deutch AY, Ongur D, Duman RS (1995). Antipsychotic drugs induce Fox protein in the thalamic paraventricular nucleus: a novel locus of antipsychotic drug action. Neuroscience 66: 337-346.
23. Dong WK, Ryu H, Wagman IH (1978). Nociceptive responses of neurons in medial thalamus and their relationship to spinothalamic pathways. J Neurophysiol 41: 1592-1613.
24. 11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology (Berl) 133: 396-404.
25. Feigin A, Ghilardi MF, Fukuda M, Mentis MJ, Dhawan V, Barnes A et al (2002). Effects of levodopa infusion on motor activation responses in Parkinson's disease. Neurology 59: 220-226.
26. Filion M (2000). Physiologic basis of dyskinesia. Ann Neurol 47: S35-S40; discussion S-1.
27. Flietstra RJ, Levant B (1998). Comparison of D2 and D3 dopamine receptor affinity of dopaminergic compounds in rat brain. Life Sci 62: 1825-1831.
28. Freeman A, Ciliax B, Bakay R, Daley J, Miller RD, Keating G et al (2001). Nigrostriatal collaterals to thalamus degenerate in parkinsonian animal models. Ann Neurol 50: 321-329.
29. Fuller TA, Russchen FT, Price JL (1987). Sources of presumptive glutamergic/aspartergic afferents to the rat ventral striatopallidal region. J Comp Neurol 258: 317-338.
30. Goldstein M, Lieberman AN, Helmer E, Koslow M, Ransohoff J, Elsworth JD et al (1988). Biochemical analysis of caudate nucleus biopsy samples from parkinsonian patients. Am Neurol 24: 685-688.
31. Groenewegen HJ (1988). Organization of the afferent connections of the mediodorsal thalamic nucleus in the rat, related to the mediodorsal-prefrontal topography. Neuroscience 24: 379-431.
32. Groenewegen HJ, Berendse HW (1994). The specificity of the 'nonspecific' midline and intralaminar thalamic nuclei. Trends Neurosci 17: 52-57.
33. 125I] beta-CIT for dopamine transporter visualization: autoradiographic evaluation in the human brain. Nucl Med Biol 24: 629-634.
34. Gurevich EV, Joyce JN (1999). Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 20: 60-80.
35. Hagelberg N, Martikainen I, Mansikka H, Hinkka S, Nagren K, Hietala J et al (2002). Dopamine D2 receptor binding in the human brain is associated with the response to painful stimulation and pain modulatory capacity. Pain 99: 273.
36. 125I]epidepride. Synapse 23: 115-123.
37. 3H]PD 128907. Psychopharmacology (Berl) 128: 240-247.
38. 125I]NCQ 298 binding to human brain extrastriated dopamine receptors. Nucl Med Biol 24: 389-393.
39. Halldin C, Farde L, Hogberg T, Mohell N, Hall H, Suhara T et al (1995). Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 36: 1275-1281.
40. Henderson JM, Carpenter K, Cartwright H, Halliday GM (2000). Degeneration of the centre median-parafascicular complex in Parkinson's disease. Ann Neurol 47: 345-352.
41. 3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin. Brain Res 648: 222-228.
42. Hershey T, Black KJ, Stambuk MK, Carl JL, McGee-Minnich LA, Perlmutter JS (1998). Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias. Proc Natl Acad Sci USA 95: 12016-12021.
43. Ilinksy IA, Jouandet ML, Goldman-Rakic PS (1985). Organization of the nigrothalamocortical system in the rhesus monkey. J Comp Neurol 236: 315-330.
44. Inoue M, Suhara T, Sudo Y, Okubo Y, Yasuno F, Kishimoto T et al (2001). Age-related reduction of extrastriatal dopamine D2 receptor measured by PET. Life Sci 69: 1079-1084.
45. Jasper H (1949). Diffuse projection systems: the integrative action of the thalamic reticular system. EEG Clin Neurophysiol 1: 405-419.
46. Jayaraman A (1985). Organization of thalamic projections in the nucleus accumbens and the caudate nucleus in cats and its relation with hippocampal and other subcortical afferents. J Comp Neurol 231: 396-420.
47. 125I]epidepride binding to dopamine D2 receptors in basal ganglia and cortex of human brain. J Pharmacol Exp Ther 257: 1253-1263.
48. Kaasinen V, Nagren K, Hietala J, Oikonen V, Vilkman H, Farde L et al (2000). Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease. Neurology 54: 1482-1487.
49. Kamei J, Saitoh A (1996). Involvement of dopamine D2 receptor-mediated functions in the modulation of morphine-induced antinociception in diabetic mouse. Neuropharmacology 35: 273-278.
50. 18F]N-allyl-5-fluoropropylepidepride. J Nucl Med 38: 1214.
51. 125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. Life Sci 53: 241-250.
52. 125I]epidepride. Brain Res 609: 237-243.
53. 123I]epidepride: characterization of uptake in the human brain. J Neural Transm Gen Sect 101: 95-103.
54. Kornetsky C, Orzack MH (1978). Physiological and behavioral correlates of attention dysfunction in schizophrenic subjects. In: Wynne LC, Cromwell RL, Matthysse S (eds). The Nature of Schizophrenia. John Wiley and Sons: New York. pp 196-204.
55. Krout KE, Belzer RE, Loewy AD (2002). Brainstem projections to midline and intralaminar thalamic nuclei of the rat. J Comp Neurol 448: 53-101.
56. 123I]epidepride single-photon emission tomography. Eur J Nucl Med 24: 483-487.
57. 11C] raclopride studies. J Cereb Blood Flow Metab 16: 42-52.
58. Little KY, McLaughlin DP, Zhang L, McFinton PR, Dalack GW, Cook Jr EH et al (1998). Brain dopamine transporter messenger RNA and binding sites in cocaine users: a postmortem study. Arch Gen Psychiatry 55: 793-799.
59. Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P (1997). Multimodality image registration by maximization of mutual information. IEEE Trans Med Imaging 16: 187-198.
60. Mai JK, Assheuer J, Paxinos G (1997). Atlas of the Human Brain. Academic Press: San Diego.
61. Matsumoto N, Minamimoto T, Graybiel AM, Kimura M (2001). Neurons in the thalamic CM-Pf complex supply striatal neurons with information about behaviorally significant sensory events. J Neurophysiol 85: 960-976.
62. Matthysse S (1978). A theory of the relationship between dopamine and attention. In: Wynne LC, Cromwell RL, Matthysse S (eds). The Nature of Schizophrenia. John Wiley and Sons: New York. pp 307-310.
63. Meador-Woodruff JH, Ibrahim HM, Richardson-Burns SM, Haroutunian V, Davis KL, Watson SJ (1999). Dopamine receptor transcript expression in schizophrenic thalamus. Biol Psychiatry 45: 28S-29S.
64. Melchitzky DS, Lewis DA (2001). Dopamine transporter-immunoreactive axons in the mediodorsal thalamic nucleus of the macaque monkey. Neuroscience 103: 1033-1042.
65. Meyerson BA, Linderoth B, Karlsson H, Ungerstedt U (1990). Microdialysis in the human brain: extracellular measurements in the thalamus of parkinsonian patients. Life Sci 46: 301-308.
66. Moga MM, Weis RP, Moore RY (1995). Efferent projections of the paraventricular thalamic nucleus in the rat. J Comp Neurol 359: 221-238.
67. Moore RY, Bloom FE (1978). Central catecholamine neuron systems: anatomy and physiology of the dopamine systems. Annu Rev Neurosci 1: 129-169.
68. Mukherjee J, Christian BT, Narayanan TK, Shi B, Mantil J (2001). Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. Neuropsychopharmacology 25: 476-488.
69. Niimi K, Kusunose M, Ono K, Yanagihara M (1990). Brainstem afferents to the intralaminar nuclei of the cat thalamus studied by the horseradish peroxidase method. J Hirnforsch 31: 107-122.
70. Oke AF, Putz C, Adams RN, Bird ED (1992). Neuroleptic treatment is an unlikely cause of elevated dopamine in thalamus of schizophrenic subjects. Psychiatry Res 45: 203-208.
71. Otake K, Nakamura Y (1998). Single midline thalamic neurons projecting to both the ventral striatum and the prefrontal cortex in the rat. Neuroscience 86: 635-649.
72. Pakkenberg B (1990). Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Arch Gen Psychiatry 47: 1023-1028.
73. Popken GJ, Bunney Jr WE, Potkin SG, Jones EG (2000). Subnucleus-specific loss of neurons in medial thalamus of schizophrenics. Proc Natl Acad Sci USA 97: 9276-9280.
74. Rico B, Cavada C (1998). Adrenergic innervation of the monkey thalamus: an immunohistochemical study. Neuroscience 84: 839-847.
75. Ruggiero DA, Anwar S, Kim J, Glickstein SB (1998). Visceral afferent pathways to the thalamus and olfactory tubercle: behavioral implications. Brain Res 799: 159-171.
76. Staley JK, Mash DC (1996). Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 16: 6100-6106.
77. Su HS, Bentivoglio M (1990). Thalamic midline cell populations projecting to the nucleus accumbens, amygdala, and hippocampus in the rat. J Comp Neurol 297: 582-593.
78. Swanson LW (1982). The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res Bull 9: 321-353.
79. Takada M, Campbell KJ, Moriizumi T, Hattori T (1990). On the origin of the dopaminergic innervation of the paraventricular thalamic nucleus. Neurosci Lett 115: 33-36.
80. Turner BH, Herkenham M (1991). Thalamoamygdaloid projections in the rat: a test of the amygdala's role in sensory processing. J Comp Neurol 313: 295-325.
81. Volkow ND, Ding YS, Fowler JS, Wang GJ (1996). Cocaine addiction: hypothesis derived from imaging studies with PET. J Addict Dis 15: 55-71.
82. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R et al (1997). Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386: 830-833.
83. Wang GJ, Volkow ND, Fowler JS, Logan J, Abumrad NN, Hitzemann RJ et al (1997). Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropsychopharmacology 16: 174-182.
84. Whitton PS (1997). Glutamatergic control over brain dopamine release in vivo and in vitro. Neurosci Biobehav Rev 21: 481-488.
85. Willis WD (1985). Nociceptive pathways: anatomy and physiology and nociceptive ascending pathways. Philos Trans R Soc Lond B Biol Sci 308: 253-270.
86. Young CD, Deutch AY (1998). The effects of thalamic paraventricular nucleus lesions on cocaine-induced locomotor activity and sensitization. Pharmacol Biochem Behav 60: 753-758.
87. Young KA, Manaye KF, Liang C, Hicks PB, German DC (2000). Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia. Biol Psychiatry 47: 944-953.
88. 18F]N-methylspiroperidol by extrastriatal dopamine receptors in schizophrenic patients. Synapse 19: 14-17.